Compare Humana Inc (HUM) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Raytheon Technologies Corp — how do they compare? Humana Inc trades at $405.49 (market cap $47.81B), while Raytheon Technologies Corp trades at $194.3 (market cap $261.85B). The key difference: Raytheon Technologies Corp is far larger — about 5.5× Humana Inc's market cap, and Raytheon Technologies Corp pays the higher dividend (1.5%). Which is the better fit depends on your goals.
| HUM | RTX | |
|---|---|---|
Market Cap | $47.81B | $261.85B |
Sector | Health | Industrials |
52-Week High | $409.42 | $212.16 |
52-Week Low | $163.67 | $149.17 |
Enterprise Value | $56.85B | $293.97B |
Dividend Yield | 0.89% | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.
The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
